AU6617900A - A method for predicting the presence of haemostatic dysfunction in a patient sample - Google Patents
A method for predicting the presence of haemostatic dysfunction in a patient sample Download PDFInfo
- Publication number
- AU6617900A AU6617900A AU66179/00A AU6617900A AU6617900A AU 6617900 A AU6617900 A AU 6617900A AU 66179/00 A AU66179/00 A AU 66179/00A AU 6617900 A AU6617900 A AU 6617900A AU 6617900 A AU6617900 A AU 6617900A
- Authority
- AU
- Australia
- Prior art keywords
- reagent
- precipitate
- patient
- sample
- formation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 94
- 229940030225 antihemorrhagics Drugs 0.000 title claims description 58
- 230000000025 haemostatic effect Effects 0.000 title claims description 58
- 230000004064 dysfunction Effects 0.000 title claims description 57
- 239000013610 patient sample Substances 0.000 title claims description 8
- 239000000523 sample Substances 0.000 claims description 91
- 238000012360 testing method Methods 0.000 claims description 87
- 239000003153 chemical reaction reagent Substances 0.000 claims description 86
- 239000002244 precipitate Substances 0.000 claims description 74
- 230000015572 biosynthetic process Effects 0.000 claims description 58
- 238000002834 transmittance Methods 0.000 claims description 47
- 102100032752 C-reactive protein Human genes 0.000 claims description 43
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 42
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 238000005259 measurement Methods 0.000 claims description 31
- 230000035602 clotting Effects 0.000 claims description 30
- 108010073385 Fibrin Proteins 0.000 claims description 29
- 102000009123 Fibrin Human genes 0.000 claims description 29
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 29
- 229950003499 fibrin Drugs 0.000 claims description 29
- 230000008859 change Effects 0.000 claims description 26
- 239000003112 inhibitor Substances 0.000 claims description 24
- 238000006116 polymerization reaction Methods 0.000 claims description 20
- 230000003287 optical effect Effects 0.000 claims description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 15
- 206010053567 Coagulopathies Diseases 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 229910052791 calcium Inorganic materials 0.000 claims description 15
- 239000011575 calcium Substances 0.000 claims description 15
- 150000001768 cations Chemical class 0.000 claims description 15
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
- 230000015271 coagulation Effects 0.000 claims description 13
- 238000005345 coagulation Methods 0.000 claims description 13
- 229960002897 heparin Drugs 0.000 claims description 13
- 229920000669 heparin Polymers 0.000 claims description 13
- 229910052751 metal Inorganic materials 0.000 claims description 13
- 239000002184 metal Substances 0.000 claims description 13
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 claims description 12
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 10
- 230000005540 biological transmission Effects 0.000 claims description 10
- 238000003018 immunoassay Methods 0.000 claims description 10
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 9
- 238000012544 monitoring process Methods 0.000 claims description 9
- 239000004019 antithrombin Substances 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 8
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 8
- 230000036962 time dependent Effects 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 102000007625 Hirudins Human genes 0.000 claims description 7
- 108010007267 Hirudins Proteins 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 229940006607 hirudin Drugs 0.000 claims description 7
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 238000002835 absorbance Methods 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 206010061818 Disease progression Diseases 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 239000002547 new drug Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims 9
- 229910052788 barium Inorganic materials 0.000 claims 7
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 208000009206 Abruptio Placentae Diseases 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 206010036608 Premature separation of placenta Diseases 0.000 claims 1
- 101710190759 Serum amyloid A protein Proteins 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960000182 blood factors Drugs 0.000 claims 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000008532 placental abruption Diseases 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000003634 thrombocyte concentrate Substances 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 30
- 108010094028 Prothrombin Proteins 0.000 description 25
- 102100027378 Prothrombin Human genes 0.000 description 25
- 229940039716 prothrombin Drugs 0.000 description 25
- 238000003556 assay Methods 0.000 description 20
- 230000002159 abnormal effect Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 230000035945 sensitivity Effects 0.000 description 10
- 230000005856 abnormality Effects 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000003154 D dimer Substances 0.000 description 7
- 230000002051 biphasic effect Effects 0.000 description 7
- 108010052295 fibrin fragment D Proteins 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 108010090444 Innovin Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008383 multiple organ dysfunction Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 101100494265 Caenorhabditis elegans best-15 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000013168 hemostasis test Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4905—Determining clotting time of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005201099A AU2005201099A1 (en) | 1999-08-12 | 2005-03-11 | Method for predicting the presence of haemostatic dysfunction in a patient sample |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09372954 | 1999-08-12 | ||
| US09/372,954 US6429017B1 (en) | 1999-02-04 | 1999-08-12 | Method for predicting the presence of haemostatic dysfunction in a patient sample |
| PCT/US2000/021022 WO2001013125A1 (en) | 1999-08-12 | 2000-08-02 | A method for predicting the presence of haemostatic dysfunction in a patient sample |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005201099A Division AU2005201099A1 (en) | 1999-08-12 | 2005-03-11 | Method for predicting the presence of haemostatic dysfunction in a patient sample |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU6617900A true AU6617900A (en) | 2001-03-13 |
Family
ID=23470305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU66179/00A Abandoned AU6617900A (en) | 1999-08-12 | 2000-08-02 | A method for predicting the presence of haemostatic dysfunction in a patient sample |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6429017B1 (enExample) |
| EP (1) | EP1200837A4 (enExample) |
| JP (1) | JP4733326B2 (enExample) |
| KR (1) | KR20020021811A (enExample) |
| AU (1) | AU6617900A (enExample) |
| CA (1) | CA2380622C (enExample) |
| WO (1) | WO2001013125A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429017B1 (en) * | 1999-02-04 | 2002-08-06 | Biomerieux | Method for predicting the presence of haemostatic dysfunction in a patient sample |
| JP4486260B2 (ja) * | 1999-02-04 | 2010-06-23 | バイオメリュー・インコーポレイテッド | 患者サンプルにおける止血機能不全の存在を予測するための方法および装置 |
| EP1522860A1 (en) * | 1999-02-04 | 2005-04-13 | bioMérieux, Inc. | A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
| AUPP971299A0 (en) * | 1999-04-12 | 1999-05-06 | South Eastern Sydney Area Health Service | Procoagulant assay |
| US7179612B2 (en) * | 2000-06-09 | 2007-02-20 | Biomerieux, Inc. | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality |
| AU6679501A (en) * | 2000-06-09 | 2001-12-24 | Akzo Nobel Nv | A method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality |
| EP1436628A2 (en) * | 2001-06-29 | 2004-07-14 | BioMerieux, Inc. | A method for predicting an increased likelihood of antiphospholipid syndrome in a patient |
| JP2005519267A (ja) * | 2002-02-27 | 2005-06-30 | バイオメリュー・インコーポレイテッド | 止血機能不全、重症感染及び全身性炎症反応症候群を診断し、監視するための方法 |
| EP1391733B1 (en) * | 2002-08-09 | 2006-12-27 | Dade Behring Marburg GmbH | Combination of CRP and D-dimer for diagnosis of deep venous thrombosis (DVT) |
| AU2003277398A1 (en) * | 2002-10-15 | 2004-05-04 | The University Of Tennessee Research Foundation | Methods for assessment of platelet aggregation |
| JP2006515670A (ja) * | 2002-11-12 | 2006-06-01 | ベクトン，ディッキンソン アンド カンパニー | バイオマーカープロファイルを用いる敗血症またはｓｉｒｓの診断 |
| US20040157242A1 (en) * | 2002-11-12 | 2004-08-12 | Becton, Dickinson And Company | Diagnosis of sepsis or SIRS using biomarker profiles |
| US7645573B2 (en) | 2002-11-12 | 2010-01-12 | Becton, Dickinson And Company | Diagnosis of sepsis or SIRS using biomarker profiles |
| GB2404981A (en) * | 2003-08-15 | 2005-02-16 | Univ Geneve | Diagnostic method for stroke |
| WO2006060386A1 (en) * | 2004-12-01 | 2006-06-08 | Biomerieux, Inc. | Method for diagnosing critically ill patients |
| US20060157647A1 (en) * | 2005-01-18 | 2006-07-20 | Becton, Dickinson And Company | Multidimensional liquid chromatography/spectrometry |
| JP2008538007A (ja) | 2005-04-15 | 2008-10-02 | ベクトン，ディッキンソン アンド カンパニー | 敗血症の診断 |
| RU2360610C1 (ru) * | 2008-01-29 | 2009-07-10 | Федеральное государственное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова Федерального агентства по высокотехнологичной медицинской помощи" | Способ прогнозирования возникновения осложнений у женщин с климактерическим синдромом на фоне заместительной гормональной терапии |
| WO2009101242A1 (en) * | 2008-02-14 | 2009-08-20 | Orion Diagnostica Oy | Method for predicting a future property |
| US8669113B2 (en) | 2008-04-03 | 2014-03-11 | Becton, Dickinson And Company | Advanced detection of sepsis |
| DE102008022884A1 (de) * | 2008-05-08 | 2009-11-12 | Zander, Rolf, Prof. Dr.Med. | Vorrichtung und Verfahren für die Blutgerinnungsdiagnostik |
| GB2547930A (en) | 2016-03-03 | 2017-09-06 | Sepsense Ltd | Assay device |
| US10872410B2 (en) | 2016-09-29 | 2020-12-22 | Animantis, Llc | Methods and apparatus for assessing immune system activity and therapeutic efficacy |
| CN108344875B (zh) * | 2017-01-22 | 2021-11-02 | 上海长岛生物技术有限公司 | 提高活化部分凝血活酶时间试剂对肝素敏感性的方法及用途 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2458287A (en) * | 1944-08-31 | 1949-01-04 | Signode Steel Strapping Co | Snubber plate |
| US3307392A (en) | 1964-05-04 | 1967-03-07 | Research Corp | Automatic prothrombin timer apparatus and method |
| US3458287A (en) | 1965-04-29 | 1969-07-29 | Medical Laboratory Automation | Method and means of determining endpoint times in blood clotting tests |
| US3658480A (en) | 1970-04-13 | 1972-04-25 | Bio Data Corp | Coagulation timing apparatus, and method |
| US4047890A (en) | 1973-11-01 | 1977-09-13 | Bio/Data Corporation | Method and apparatus for determining deficiencies in enzymatic reactors particularly clotting factor levels in blood plasmas |
| SU590665A1 (ru) | 1976-02-11 | 1978-01-30 | Новосибирский государственный медицинский институт | Способ исследовани процесса свертывани крови |
| US4040788A (en) * | 1976-04-05 | 1977-08-09 | Sanford L. Simons | Apparatus, instrumentation, and method for comparing samples |
| US4157871A (en) * | 1976-06-02 | 1979-06-12 | Beckman Instruments, Inc. | System for rate immunonephelometric analysis |
| DE2635081C3 (de) | 1976-08-04 | 1980-08-07 | Bio/Data Corp., Willow Grove, Pa. (V.St.A.) | Verfahren und Vorrichtung zur Bestimmung von Blutplasma-Gerinnungsfaktorpegeln |
| FR2364453A1 (fr) | 1976-09-08 | 1978-04-07 | Lacombe Pierre | Dispositif electronique apportant un perfectionnement aux appareils destines a analyser la coagulation sanguine : prothrombinometre citrate-oxalate |
| US4199748A (en) | 1976-11-01 | 1980-04-22 | Rush-Presbyterian-St. Luke's Medical Center | Automated method and apparatus for classification of cells with application to the diagnosis of anemia |
| JPS5451893A (en) | 1977-09-30 | 1979-04-24 | Sankyo Co | Measuring of blood coagulating time |
| JPS5822703B2 (ja) | 1978-08-30 | 1983-05-10 | 三共株式会社 | 血液凝固測定方法 |
| US4289498A (en) | 1979-01-08 | 1981-09-15 | Ortho Diagnostics, Inc. | One-stage prothrombin assay and compositions useful therein |
| AU543007B2 (en) * | 1980-04-15 | 1985-03-28 | Technicon Instruments Corportion | Agglutination immunoassay |
| US4766083A (en) | 1982-04-04 | 1988-08-23 | Wako Pure Chemical Industries, Ltd. | Method for the photometric determination of biological agglutination |
| SU1076086A1 (ru) | 1982-12-28 | 1984-02-29 | Всесоюзный Научно-Исследовательский И Конструкторский Институт Медицинской Лабораторной Техники | Гемокоагулограф |
| EP0115459A3 (en) | 1983-01-26 | 1986-11-20 | University Of Medicine And Dentistry Of New Jersey | Hematological prediction of sepsis and other disease states |
| US4705756A (en) | 1983-01-26 | 1987-11-10 | University Of Medicine And Dentistry Of New Jersey | Method of determining the existence and/or the monitoring of a pathological condition in a mammal |
| JPS59203959A (ja) | 1983-05-04 | 1984-11-19 | Toa Medical Electronics Co Ltd | 血液凝固時間測定装置 |
| JPH0695095B2 (ja) | 1983-11-25 | 1994-11-24 | 株式会社島津製作所 | 全自動血液分析装置 |
| DE3502878A1 (de) | 1985-01-29 | 1986-07-31 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur bestimmung des fibrinolytischen zustands von plasma |
| JPS61272655A (ja) | 1985-05-28 | 1986-12-02 | Iryo Kogaku Kenkyusho:Kk | 血小板凝集能の定量的判定方法 |
| GB8516081D0 (en) | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
| US4902630A (en) | 1985-07-22 | 1990-02-20 | Abbott Laboratories | Fluorescence polarization immunoassy and reagents for measurement of c-reactive protein |
| US5593897A (en) | 1988-04-04 | 1997-01-14 | Northwestern University | Binding of immune complexes by modified forms of C-reactive protein |
| AU633488B2 (en) | 1988-04-04 | 1993-02-04 | Northwestern University | Binding of immune complexes by modified forms of c-reactive protein |
| US4965725B1 (en) | 1988-04-08 | 1996-05-07 | Neuromedical Systems Inc | Neural network based automated cytological specimen classification system and method |
| US5156974A (en) | 1988-05-27 | 1992-10-20 | Biodata Corporation | Method for determining the fibrinogen level of a blood sample |
| US5003065A (en) | 1988-06-14 | 1991-03-26 | Carey Merritt | Compounds and process for measuring c-reactive protein |
| US5697369A (en) | 1988-12-22 | 1997-12-16 | Biofield Corp. | Method and apparatus for disease, injury and bodily condition screening or sensing |
| DE3901458A1 (de) * | 1989-01-19 | 1990-07-26 | Behringwerke Ag | Verwendung von zwei- oder dreiwertigen kationen in immunchemischen tests |
| US5055412A (en) * | 1989-03-21 | 1991-10-08 | Proksch Gary J | Factor sensitive reagent for testing of blood coagulation containing ellagic acid and divalent metal ions and method of making the same |
| US5500345A (en) | 1989-04-25 | 1996-03-19 | Iatron Laboratories, Inc. | Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein |
| JPH04505857A (ja) | 1989-06-27 | 1992-10-15 | ラッシュ―プレズビティリアン―セント ルークス メディカル センター | Ｃ反応性蛋白質に対するモノクローナル抗体 |
| US5051357A (en) | 1989-07-14 | 1991-09-24 | Board Of Trustees Operating Michigan State University | Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor |
| WO1991001383A1 (en) | 1989-07-14 | 1991-02-07 | Michigan State University | Method for diagnosing blood clotting disorders |
| JP3055933B2 (ja) | 1989-07-20 | 2000-06-26 | アナリティカル・コントロール・システムズ・インコーポレーテッド | 改良された安定な凝固対照 |
| SU1691741A1 (ru) | 1989-08-25 | 1991-11-15 | Донецкий государственный медицинский институт | Способ прогнозировани геморрагических осложнений при травматической болезни |
| US4998535A (en) | 1989-09-05 | 1991-03-12 | Univ. of Washington New England Medical Center Hospitals, Inc. | Thrombolysis predictive instrument |
| US5262303A (en) * | 1989-10-13 | 1993-11-16 | Trustees Of Boston University | Ligand/anti-ligand assays for adherent proteins |
| IE904244A1 (en) | 1989-12-01 | 1991-06-05 | Akzo Nv | Direct fibrinogen assay |
| US5646046A (en) * | 1989-12-01 | 1997-07-08 | Akzo Nobel N.V. | Method and instrument for automatically performing analysis relating to thrombosis and hemostasis |
| US5169786A (en) | 1989-12-19 | 1992-12-08 | Ortho Diagnostic Systems, Inc. | Method of determining levels of extrinsic and intrinsic clotting factors and protein c |
| ATE140034T1 (de) | 1990-04-17 | 1996-07-15 | Analytical Control Syst Inc | Koagulationsassays und reagenzien |
| US5862304A (en) | 1990-05-21 | 1999-01-19 | Board Of Regents, The University Of Texas System | Method for predicting the future occurrence of clinically occult or non-existent medical conditions |
| US5218529A (en) | 1990-07-30 | 1993-06-08 | University Of Georgia Research Foundation, Inc. | Neural network system and methods for analysis of organic materials and structures using spectral data |
| CA2052316C (en) * | 1990-10-10 | 1997-12-23 | Edward A. Oakley | Sludge flow measuring system |
| JPH04254760A (ja) | 1991-01-30 | 1992-09-10 | Eiken Chem Co Ltd | 血清アミロイドａ標準物質、およびその設定方法 |
| US5221628A (en) | 1991-03-19 | 1993-06-22 | Northwestern University | Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component |
| RU2012877C1 (ru) | 1991-04-01 | 1994-05-15 | Белорусский научно-исследовательский институт охраны материнства и детства | Способ прогнозирования синдрома дыхательных расстройств у недоношенных новорожденных |
| DE69122752T2 (de) | 1991-08-02 | 1997-04-10 | Grifols Grupo Sa | Verfahren und Vorrichtung zur Bestimmung der Gerinnungszeit von Blut und Plasma |
| US5716795A (en) | 1991-10-04 | 1998-02-10 | Matschiner; John T. | Thrombomodulin-based coagulometric assay of the protein C system |
| WO1993007491A1 (en) | 1991-10-04 | 1993-04-15 | Board Of Regents Of The University Of Nebraska | A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins |
| CA2121680C (en) | 1991-11-04 | 2005-03-22 | Andrew E. Senyei | Screening method for identifying women at increased risk for preterm delivery |
| JPH05180835A (ja) | 1991-12-27 | 1993-07-23 | S R L:Kk | ループスアンチコアグラントの測定方法 |
| US5318958A (en) | 1992-05-29 | 1994-06-07 | Queen's University At Kingston | Amyloid precursor protein |
| JP2934557B2 (ja) | 1992-07-10 | 1999-08-16 | 国際試薬株式会社 | 血液凝固時間測定方法とその装置 |
| JPH0636061A (ja) | 1992-07-21 | 1994-02-10 | Fujitsu Ltd | 階層型ニューラルネットワークの学習方式 |
| US5388164A (en) | 1992-08-19 | 1995-02-07 | Olympus Optical Co., Ltd. | Method for judging particle agglutination patterns using neural networks |
| JP3224607B2 (ja) * | 1992-09-11 | 2001-11-05 | 株式会社アズウェル | 血液凝固第ｘｉｉｉ因子活性測定方法および該測定用試薬キット |
| US5369484A (en) | 1992-11-09 | 1994-11-29 | Akzo N.V. | Multiple discrete analyzer test apparatus and method |
| US5358852A (en) | 1992-12-21 | 1994-10-25 | Eastman Kodak Company | Use of calcium in immunoassay for measurement of C-reactive protein |
| RU2070327C1 (ru) | 1992-12-25 | 1996-12-10 | Безруков Александр Васильевич | Устройство для измерения времени свертывания крови |
| US5344754A (en) | 1993-01-13 | 1994-09-06 | Avocet Medical, Inc. | Assay timed by electrical resistance change and test strip |
| JP2938302B2 (ja) | 1993-02-25 | 1999-08-23 | 国際試薬株式会社 | 血液凝固時間測定方法とその装置 |
| JPH06249857A (ja) | 1993-02-26 | 1994-09-09 | Hitachi Ltd | 自動分析装置 |
| RU2061953C1 (ru) | 1993-03-10 | 1996-06-10 | Тюменский государственный медицинский институт МЗ РФ | Способ количественного определения общей коагуляционной активности тромбоцитов |
| US5670329A (en) | 1993-05-28 | 1997-09-23 | Cardiovascular Diagnostics, Inc. | Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field |
| ATE177536T1 (de) * | 1993-06-30 | 1999-03-15 | Diagnostische Forsch Stiftung | Messung des aktivierten partiellen thromboplastinzeit (aptt) in einer einstufen- reaktion |
| AU688365B2 (en) | 1993-08-16 | 1998-03-12 | Biomerieux, Inc. | Method and instrument for automatically performing analysis relating to thrombosis and hemostasis |
| US5526111A (en) | 1993-08-31 | 1996-06-11 | Boehringer Mannheim Corporation | Method and apparatus for calculating a coagulation characteristic of a sample of blood a blood fraction or a control |
| US5472852A (en) | 1993-09-15 | 1995-12-05 | Oklahoma Medical Research Foundation | Assay for detection of selective Protein C inhibition by patients |
| US5473732A (en) | 1993-11-02 | 1995-12-05 | Chang; Hou-Mei H. | Relational artificial intelligence system |
| US5553616A (en) | 1993-11-30 | 1996-09-10 | Florida Institute Of Technology | Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator |
| US5856114A (en) | 1994-03-21 | 1999-01-05 | The University Of Vermont | Immunologic detection of factor VA fragments in hemorrhagic and thrombotic clinical settings |
| ATE202633T1 (de) | 1994-04-28 | 2001-07-15 | Dade Behring Inc | Kalibrator für prothrombin-zeit-assays |
| AU1287595A (en) | 1994-08-26 | 1996-03-22 | Immtech International, Inc. | A mutant protein and methods and materials for making and using it |
| US5504011A (en) | 1994-10-21 | 1996-04-02 | International Technidyne Corporation | Portable test apparatus and associated method of performing a blood coagulation test |
| SE9403833D0 (sv) | 1994-11-08 | 1994-11-08 | Global Hemostasis Inst Mgr Ab | Analysförfarande och kit |
| US5705395A (en) | 1994-11-14 | 1998-01-06 | The Scripps Research Institute | Method for diagnosis of thrombotic disorders |
| US5567596A (en) | 1994-12-29 | 1996-10-22 | Research Foundation Of State University Of New York | Rapid assay of activators and inhibitors of clotting |
| AU4634896A (en) | 1995-01-10 | 1996-07-31 | Hendrik Coenraad Hemker | Methods of determining endogenous thrombin potential (etp) and thrombin substrates for use in said methods |
| US5708591A (en) | 1995-02-14 | 1998-01-13 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions |
| US5646045A (en) * | 1995-05-17 | 1997-07-08 | Protein Technologies International | Cellulose in food matrix quantification |
| US6321164B1 (en) * | 1995-06-07 | 2001-11-20 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade |
| US6429017B1 (en) * | 1999-02-04 | 2002-08-06 | Biomerieux | Method for predicting the presence of haemostatic dysfunction in a patient sample |
| US5780255A (en) | 1995-06-09 | 1998-07-14 | Instrumentation Laboratory, S.P.A. | Protein C pathway screening test |
| AU711163B2 (en) | 1995-07-21 | 1999-10-07 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The | Method for the quantitative measurement of human acute phase serum amyloid a protein; recombinant protein; specific antibody |
| US5766869A (en) | 1995-11-30 | 1998-06-16 | Ahs Hospital Corp. | Factor V ratio blood test for susceptibility to thromboembolism |
| JP3743918B2 (ja) | 1996-03-22 | 2006-02-08 | デイド、ベーリング、インコーポレイテッド | コンビネーション試薬保持およびテスト装置 |
| JPH1026621A (ja) | 1996-07-12 | 1998-01-27 | Dai Ichi Pure Chem Co Ltd | イムノアッセイ法 |
| US5684007A (en) | 1996-09-05 | 1997-11-04 | Otsuka Pharmaceutical Co., Ltd. | Methods for inhibiting cardiac fibroblast growth and cardiac fibrosis |
| JP3876022B2 (ja) | 1996-09-26 | 2007-01-31 | 生化学工業株式会社 | 血液凝固時間に影響を与える物質の定量方法 |
| US5981285A (en) | 1996-10-21 | 1999-11-09 | Carroll; Wallace E. | Method and apparatus for determining anticoagulant therapy factors |
| EP0841566A1 (en) | 1996-11-11 | 1998-05-13 | Pentapharm A.G. | Positive control plasma for lupus anticoagulant |
| WO1998043630A1 (en) | 1997-04-02 | 1998-10-08 | Brigham And Women's Hospital, Inc. | Means of ascertaining an individual's risk profile for atherosclerotic disease |
| US6010911A (en) | 1997-04-30 | 2000-01-04 | Medtronic, Inc. | Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique |
| PT947585E (pt) | 1998-03-19 | 2001-11-30 | Instrumentation Lab Spa | Metodo in vitro melhorado, kits e reagentes para a peaquisa de defeitos de coagulacao sanguinea |
| US7179612B2 (en) * | 2000-06-09 | 2007-02-20 | Biomerieux, Inc. | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality |
-
1999
- 1999-08-12 US US09/372,954 patent/US6429017B1/en not_active Expired - Lifetime
-
2000
- 2000-08-02 WO PCT/US2000/021022 patent/WO2001013125A1/en not_active Ceased
- 2000-08-02 CA CA2380622A patent/CA2380622C/en not_active Expired - Fee Related
- 2000-08-02 JP JP2001517176A patent/JP4733326B2/ja not_active Expired - Fee Related
- 2000-08-02 KR KR1020027001897A patent/KR20020021811A/ko not_active Ceased
- 2000-08-02 EP EP00953788A patent/EP1200837A4/en not_active Withdrawn
- 2000-08-02 AU AU66179/00A patent/AU6617900A/en not_active Abandoned
-
2002
- 2002-05-28 US US10/156,462 patent/US20030049851A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003507713A (ja) | 2003-02-25 |
| WO2001013125A1 (en) | 2001-02-22 |
| US6429017B1 (en) | 2002-08-06 |
| CA2380622A1 (en) | 2001-02-22 |
| CA2380622C (en) | 2013-12-10 |
| JP4733326B2 (ja) | 2011-07-27 |
| EP1200837A1 (en) | 2002-05-02 |
| KR20020021811A (ko) | 2002-03-22 |
| US20030049851A1 (en) | 2003-03-13 |
| EP1200837A4 (en) | 2003-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008201621B8 (en) | A method for predicting the presence of haemostatic dysfunction in a patient sample | |
| CA2380622C (en) | A method for predicting the presence of haemostatic dysfunction in a patient sample | |
| Northup et al. | Coagulation in liver disease: a guide for the clinician | |
| Lim et al. | A review of global coagulation assays—is there a role in thrombosis risk prediction? | |
| Downey et al. | Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis | |
| Favaloro | Laboratory testing in disseminated intravascular coagulation | |
| US20070155018A1 (en) | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality | |
| US7211438B2 (en) | Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample | |
| Di Castelnuovo et al. | Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke | |
| CA2847839A1 (en) | Diagnostic assay to predict cardiovascular risk | |
| US6898532B1 (en) | Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample | |
| AU2001266795A1 (en) | A method for detecting a lipoprotein-acute phase protein complex | |
| US7179612B2 (en) | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality | |
| RU2217754C1 (ru) | Способ прогнозирования клинического течения ишемического инсульта | |
| AU2005201099A1 (en) | Method for predicting the presence of haemostatic dysfunction in a patient sample | |
| RU2621298C1 (ru) | Способ прогнозирования тромбоэмболических осложнений | |
| Kilanowska et al. | Aspirin ‘responsiveness’,‘nonresponsiveness’ or ‘resistance’: a putative role for von Willebrand factor? | |
| Bonhomme et al. | Laboratory testing of hemostasis | |
| Abdelwahab | Laboratory Diagnosis of Less Common Acquired and Congenital Thrombophilic | |
| Rodgers et al. | Hemostasis screening assays | |
| EP1522860A1 (en) | A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample | |
| KR101608134B1 (ko) | 단백질 ｚ의 혈액 항응고기능 분석방법 | |
| Rudrapatna et al. | Preoperative coagulation assessment for the neurosurgical patient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: BIOMERIEUX, INC. Free format text: THE FORMER OWNER WAS: AKZO NOBEL N.V. |